Algorithms Implemented for Cancer Gene Searching and Classifications

Understanding the gene expression is an important factor to cancer diagnosis. One target of this understanding is implementing cancer gene search and classification methods. However, cancer gene search and classification is a challenge in that there is no an obvious exact algorithm that can be implemented individually for various cancer cells. In this paper a research is con-ducted through the most common top ranked algorithms implemented for cancer gene search and classification, and how they are implemented to reach a better performance. The paper will distinguish algorithms implemented for Bio image analysis for cancer cells and algorithms implemented based on DNA array data. The main purpose of this paper is to explore a road map towards presenting the most current algorithms implemented for cancer gene search and classification

Applied Computational Techniques on Schizophrenia Using Genetic Mutations

[Abstract] Schizophrenia is a complex disease, with both genetic and environmental influence. Machine learning techniques can be used to associate different genetic variations at different genes with a (schizophrenic or non-schizophrenic) phenotype. Several machine learning techniques were applied to schizophrenia data to obtain the results presented in this study. Considering these data, Quantitative Genotype – Disease Relationships (QDGRs) can be used for disease prediction. One of the best machine learning-based models obtained after this exhaustive comparative study was implemented online; this model is an artificial neural network (ANN). Thus, the tool offers the possibility to introduce Single Nucleotide Polymorphism (SNP) sequences in order to classify a patient with schizophrenia. Besides this comparative study, a method for variable selection, based on ANNs and evolutionary computation (EC), is also presented. This method uses half the number of variables as the original ANN and the variables obtained are among those found in other publications. In the future, QDGR models based on nucleic acid information could be expanded to other diseases.Programa Iberoamericano de Ciencia y Tecnología para el Desarrollo; 209RT-0366Xunta de Galicia; 10SIN105004PRInstituto de Salud Carlos III; RD07/0067/0005Xunta de Galicia; Ref. 2009/5

A Comparative Analysis of Data Mining Techniques on Breast Cancer Diagnosis Data using WEKA Toolbox

Abstract—Breast cancer is considered the second most common cancer in women compared to all other cancers. It is fatal in less than half of all cases and is the main cause of mortality in women. It accounts for 16% of all cancer mortalities worldwide. Early diagnosis of breast cancer increases the chance of recovery. Data mining techniques can be utilized in the early diagnosis of breast cancer. In this paper, an academic experimental breast cancer dataset is used to perform a data mining practical experiment using the Waikato Environment for Knowledge Analysis (WEKA) tool. The WEKA Java application represents a rich resource for conducting performance metrics during the execution of experiments. Pre-processing and feature extraction are used to optimize the data. The classification process used in this study was summarized through thirteen experiments. Additionally, 10 experiments using various different classification algorithms were conducted. The introduced algorithms were: Naïve Bayes, Logistic Regression, Lazy IBK (Instance-Bases learning with parameter K), Lazy Kstar, Lazy Locally Weighted Learner, Rules ZeroR, Decision Stump, Decision Trees J48, Random Forest and Random Trees. The process of producing a predictive model was automated with the use of classification accuracy. Further, several experiments on classification of Wisconsin Diagnostic Breast Cancer and Wisconsin Breast Cancer, were conducted to compare the success rates of the different methods. Results conclude that Lazy IBK classifier k-NN can achieve 98% accuracy among other classifiers. The main advantages of the study were the compactness of using 13 different data mining models and 10 different performance measurements, and plotting figures of classifications errors

INTEGRATIVE ANALYSIS OF OMICS DATA IN ADULT GLIOMA AND OTHER TCGA CANCERS TO GUIDE PRECISION MEDICINE

Transcriptomic profiling and gene expression signatures have been widely applied as effective approaches for enhancing the molecular classification, diagnosis, prognosis or prediction of therapeutic response towards personalized therapy for cancer patients. Thanks to modern genome-wide profiling technology, scientists are able to build engines leveraging massive genomic variations and integrating with clinical data to identify “at risk” individuals for the sake of prevention, diagnosis and therapeutic interventions. In my graduate work for my Ph.D. thesis, I have investigated genomic sequencing data mining to comprehensively characterise molecular classifications and aberrant genomic events associated with clinical prognosis and treatment response, through applying high-dimensional omics genomic data to promote the understanding of gene signatures and somatic molecular alterations contributing to cancer progression and clinical outcomes. Following this motivation, my dissertation has been focused on the following three topics in translational genomics. 1) Characterization of transcriptomic plasticity and its association with the tumor microenvironment in glioblastoma (GBM). I have integrated transcriptomic, genomic, protein and clinical data to increase the accuracy of GBM classification, and identify the association between the GBM mesenchymal subtype and reduced tumorpurity, accompanied with increased presence of tumor-associated microglia. Then I have tackled the sole source of microglial as intrinsic tumor bulk but not their corresponding neurosphere cells through both transcriptional and protein level analysis using a panel of sphere-forming glioma cultures and their parent GBM samples.FurthermoreI have demonstrated my hypothesis through longitudinal analysis of paired primary and recurrent GBM samples that the phenotypic alterations of GBM subtypes are not due to intrinsic proneural-to-mesenchymal transition in tumor cells, rather it is intertwined with increased level of microglia upon disease recurrence. Collectively I have elucidated the critical role of tumor microenvironment (Microglia and macrophages from central nervous system) contributing to the intra-tumor heterogeneity and accurate classification of GBM patients based on transcriptomic profiling, which will not only significantly impact on clinical perspective but also pave the way for preclinical cancer research. 2) Identification of prognostic gene signatures that stratify adult diffuse glioma patientsharboring1p/19q co-deletions. I have compared multiple statistical methods and derived a gene signature significantly associated with survival by applying a machine learning algorithm. Then I have identified inflammatory response and acetylation activity that associated with malignant progression of 1p/19q co-deleted glioma. In addition, I showed this signature translates to other types of adult diffuse glioma, suggesting its universality in the pathobiology of other subset gliomas. My efforts on integrative data analysis of this highly curated data set usingoptimizedstatistical models will reflect the pending update to WHO classification system oftumorsin the central nervous system (CNS). 3) Comprehensive characterization of somatic fusion transcripts in Pan-Cancers. I have identified a panel of novel fusion transcripts across all of TCGA cancer types through transcriptomic profiling. Then I have predicted fusion proteins with kinase activity and hub function of pathway network based on the annotation of genetically mobile domains and functional domain architectures. I have evaluated a panel of in -frame gene fusions as potential driver mutations based on network fusion centrality hypothesis. I have also characterised the emerging complexity of genetic architecture in fusion transcripts through integrating genomic structure and somatic variants and delineating the distinct genomic patterns of fusion events across different cancer types. Overall my exploration of the pathogenetic impact and clinical relevance of candidate gene fusions have provided fundamental insights into the management of a subset of cancer patients by predicting the oncogenic signalling and specific drug targets encoded by these fusion genes. Taken together, the translational genomic research I have conducted during my Ph.D. study will shed new light on precision medicine and contribute to the cancer research community. The novel classification concept, gene signature and fusion transcripts I have identified will address several hotly debated issues in translational genomics, such as complex interactions between tumor bulks and their adjacent microenvironments, prognostic markers for clinical diagnostics and personalized therapy, distinct patterns of genomic structure alterations and oncogenic events in different cancer types, therefore facilitating our understanding of genomic alterations and moving us towards the development of precision medicine

DNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer

Germline pathogenic mutations in BRCA1 increase risk of developing breast cancer. Screening for mutations in BRCA1 frequently identifies sequence variants of unknown pathogenicity and recent work has aimed to develop methods for determining pathogenicity. We previously observed that tumor DNA methylation can differentiate BRCA1-mutated from BRCA1-wild type tumors. We hypothesized that we could predict pathogenicity of variants based on DNA methylation profiles of tumors that had arisen in carriers of unclassified variants. We selected 150 FFPE breast tumor DNA samples [47 BRCA1 pathogenic mutation carriers, 65 BRCAx (BRCA1-wild type), 38 BRCA1 test variants] and analyzed a subset (n=54) using the Illumina 450K methylation platform, using the remaining samples for bisulphite pyrosequencing validation. Three validated markers (BACH2, C8orf31, and LOC654342) were combined with sequence bioinformatics in a model to predict pathogenicity of 27 variants (independent test set). Predictions were compared with standard multifactorial likelihood analysis. Prediction was consistent for c.5194-12G>A (IVS 19-12 G>A) (P>0.99); 13 variants were considered not pathogenic or likely not pathogenic using both approaches. We conclude that tumor DNA methylation data alone has potential to be used in prediction of BRCA1 variant pathogenicity but is not independent of estrogen receptor status and grade, which are used in current multifactorial models to predict pathogenicity